- Home
- EVI vs RIGL Comparison
EVI vs RIGL Comparison
Compare EVI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVI
- RIGL
- Stock Information
- Founded
- EVI 1959
- RIGL 1996
- Country
- EVI United States
- RIGL United States
- Employees
- EVI N/A
- RIGL N/A
- Industry
- EVI Other Consumer Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- EVI Consumer Discretionary
- RIGL Health Care
- Exchange
- EVI Nasdaq
- RIGL Nasdaq
- Market Cap
- EVI 353.9M
- RIGL 335.5M
- IPO Year
- EVI N/A
- RIGL 2000
- Fundamental
- Price
- EVI $27.13
- RIGL $34.22
- Analyst Decision
- EVI Strong Buy
- RIGL Buy
- Analyst Count
- EVI 1
- RIGL 5
- Target Price
- EVI $33.00
- RIGL $38.20
- AVG Volume (30 Days)
- EVI 11.9K
- RIGL 710.9K
- Earning Date
- EVI 09-11-2025
- RIGL 11-06-2025
- Dividend Yield
- EVI 1.20%
- RIGL N/A
- EPS Growth
- EVI 32.43
- RIGL N/A
- EPS
- EVI 0.49
- RIGL 5.43
- Revenue
- EVI $389,830,000.00
- RIGL $267,921,000.00
- Revenue This Year
- EVI $13.40
- RIGL $59.93
- Revenue Next Year
- EVI N/A
- RIGL N/A
- P/E Ratio
- EVI $56.07
- RIGL $6.33
- Revenue Growth
- EVI 10.26
- RIGL 105.62
- 52 Week Low
- EVI $14.99
- RIGL $13.37
- 52 Week High
- EVI $29.29
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- EVI 53.66
- RIGL 43.91
- Support Level
- EVI $27.24
- RIGL $35.56
- Resistance Level
- EVI $29.29
- RIGL $38.72
- Average True Range (ATR)
- EVI 1.02
- RIGL 2.19
- MACD
- EVI -0.19
- RIGL -1.19
- Stochastic Oscillator
- EVI 11.27
- RIGL 2.97
About EVI EVI Industries Inc.
EVI Industries Inc through its subsidiaries, is a distributor that sells, leases, and rents commercial, industrial, and vended laundry and dry cleaning equipment and steam and hot water boilers manufactured by others, supplies related replacement parts and accessories, designs and plans turn-key laundry, dry cleaning, and boiler systems, and provides installation and maintenance services to its customers, which include commercial, industrial, institutional, government, and retail customers. These activities are conducted in the United States, Canada, the Caribbean, and Latin America.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.